Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry to track rare brain cancer spread

NCT ID NCT06146010

Knowledge-focused Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study creates a registry for people with leptomeningeal disease, a rare condition where cancer spreads to the lining of the brain and spinal cord. Researchers will collect information on how the disease progresses, what treatments are used, and any side effects. The goal is to better understand the disease and improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The majority of patients observed are capable of giving consent. However, tumors of the central nervous system can lead to a psychosyndrome that restricts the patient's ability to give consent. Nevertheless, it is important to document and evaluate the course of the disease and the effects of the therapies administered, especially in these patients.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with leptomeningeal disease * Written consent of the patient or legal guardian. * Capacity to give consent or legal guardianship * Age ≥ 18 years Exclusion Criteria: * Lack of informed consent from the patient * Lack of capacity to consent on the part of the person concerned or lack of legal guardianship * Age \< 18 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leptomeningeal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Meningeal Neoplasms neoplastic meningitis tumor of meninges

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leptomeningeal disease Meningeal neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Diakonie Klinikum GmbH • Jung-Stilling-KrankenhausAbteilung Neurochirurgie

    RECRUITING

    Siegen, 57074, Germany

  • Klinikum rechts der Isar | Technische Universität München; Klinik für Radioonkologie und Strahlentherapie

    RECRUITING

    München, 81675, Germany

  • University Hospital Tübingen, Neurooncology

    RECRUITING

    Tübingen, 72076, Germany

  • Universitätsklinikum Bonn Klinik und Poliklinik für Neurologie

    RECRUITING

    Bonn, 53127, Germany

  • Universitätsklinikum Ulm; Klinik für Innere Medizin III

    RECRUITING

    Ulm, 89081, Germany

  • Universitätsmedizin Mannheim Universitätsklinikum Mannheim GmbH Klinik für Neurologie

    RECRUITING

    Mannheim, 68167, Germany

  • Überörtliche Gemeinschaftspraxis für Hämatologie und Onkologie

    NOT_YET_RECRUITING

    Münster, 48153, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.